Medical management of diabetic retinopathy: An overview

Archives of Iranian Medicine

Volumn 15, Issue 10, 2012, Pages 635-640

  Malek, Mojtaba ^a   Khamseh, Mohammad E ^a   Aghili, Rokhsareh ^a   Emami, Zahra ^a   Najafi, Laily ^a   Baradaran, Hamid R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Management; Retinopathy

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AFLIBERCEPT; ALDOSE REDUCTASE INHIBITOR; ANGIOTENSIN ANTAGONIST; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; FENOFIBRATE; GLITAZONE DERIVATIVE; GROWTH HORMONE INHIBITOR; HORMONE RELEASE INHIBITING FACTOR; INSULIN LIKE GROWTH FACTOR 1 INHIBITOR; PENTOXIFYLLINE; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; ROSIGLITAZONE; RUBOXISTAURIN; SALICYLIC ACID; SIMVASTATIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ARTICLE; BLOOD PRESSURE REGULATION; DIABETIC MACULAR EDEMA; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG MEGADOSE; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; LIPID CONTROL; METABOLIC REGULATION; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; PRIMARY PREVENTION; PROTEIN KINASE C; RISK FACTORS; SECONDARY PREVENTION; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867266247     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. International Diabetes Federation. Diabetes atlas. November 2011. Available from: URL: http://www.idf.org/diabetesatlas/5e/the-global-burden
2. National Health and Medical Research Council. Clinical Practice Guidelines for the Management of Diabetic Retinopathy. Canberra: NHMRC; 1997.
3. Dodson PM. Management of diabetic retinopathy: could lipid-lower- ing be a worthwhile treatment modality? Eye (Lond). 2009; 23: 997-1003.
4. Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Kham-seh ME, Kharazmi E, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One. 2011; 6: e26864.
5. US Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2005.
6. June C, Yusuf A. Diabetic Retinopathy: A Review. Drug Dev Res. 2008; 69: 1-14.
7. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiological Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol.1984; 102: 520-526.
8. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-840.
9. Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011; 94: 352-363.
10. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic reti-nopathy. JAMA. 1988; 260: 2864-2871
11. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004; 27: 2540-2553.
12. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977-986.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
14. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor re-ceptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes. 2001; 50: 444-454.
15. Khamseh ME, Ansari M, Malek M, Shafiee G, Baradaran H. Effects of a structured self-monitoring of blood glucose method on patient self-management behavior and metabolic outcomes in type 2 diabetes mellitus. J Diabetes Sci Technol. 2011; 5: 388-393.
16. Alghadyan AA. Diabetic Retinopathy-An Update. Saudi J Ophthal-mol.2011; 25: 99-111.
17. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
18. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61: 1086-1097.
19. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. ACCORD Study Group; ACCORD Eye Study Group. N Engl J Med. 2010; 363: 233-244.
20. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia. 1996; 39: 1646-1654.
21. Mohamed Q, Gillies MC, Wong TY Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298: 902-916.
22. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy Curr Opin Ophthalmol. 2004; 15: 508-518.
23. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996; 114: 1079-1084.
24. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004; 45: 910-918.
25. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes May. 1969; 18: 285-291.
26. Nadal JA, Scicli GM, Carbini LA, Scicli AG. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB. Am J Physiol Heart Circ Physiol. 2002; 282: H739-H748.
27. Sarlos S, Wilkinson-Berka JL. The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci. 2005; 46: 1069-1077.
28. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study pro-gramme. Eye. 2010; 24: 1-6.
29. Strain WD, Chaturvedi N. The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst. 2002; 3: 243-246.
30. Mori F, Hikichi T, Nagaoka T, Takahashi J, Kitaya N, Yoshida A. Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. Br J Ophthalmol. 2002; 86: 1172-1174.
31. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351: 28-31.
32. No authors listed. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253-259.
33. Khamseh ME, Safarnejad B, Baradaran HR The effect of captopril on progression of retinopathy in type 2 diabetes. Diabetes Technol Ther. 2009; 11: 711-715.
34. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008; 372: 1394-1402.
35. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008; 372: 1385-1393.
36. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-1487.
37. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy Diabetes Metab Rev. 1997; 13: 37-50.
38. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy Curr Opin Ophthalmol. 2004; 15: 508-518.
39. Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112: 1747-1757.
40. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmol-ogy. 2006; 113: 23-28.
41. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113: 1706-1712.
42. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113: 1695. e1-15.
43. June C, Yusuf A. Diabetic retinopathy: a review. Drug Develop Res. 2008; 69: 1-14.
44. Shams N, Ianchulev T Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am. 2006; 19: 335-344.
45. Algvere PV, Steén B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 2008; 86: 482-489.
46. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravit real injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007; 125: 1363-1366.
47. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26: 352-354.
48. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008; 28: 1053-1060
49. Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF A three-year trial of atromid therapy in exudative diabetic retinopathy Diabetes. 1968; 17: 458-467.
50. Harrold BP, Marmion VJ, Gough KR A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes. 1969; 18: 285-291.
51. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK. 1974; 94: 554-562.
52. Dodson PM. Management of diabetic retinopathy: could lipid-lower-ing be a worthwhile treatment modality? Eye. 2009; 23: 997-1003
53. Dodson PM, Galton DJ, Winder AF. Retinal vascular abnormalities in the hyperlipidemias. Trans Ophthalmol Soc UK. 1981; 101: 17-21.
54. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-696.
55. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol. 2007; 99: 103i-111i.
56. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; 370: 1687-1697.
57. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18: 1450-1452.
58. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008; 30: 65-84.
59. Kopchick JJ, Okada S. Growth hormone receptor antagonists: discov-ery and potential uses. Growth Horm IGF Res. 2001; 11(suppl A): S103-S109.
60. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-De-Hoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000; 23: 504-509.
61. Sjølie AK, Møller F Medical management of diabetic retinopathy Diabet Med. 2004; 21: 666-672.
62. Hernández C, Carrasco E, Casamitjana R, Deulofeu R, García-Arumí J, Simó R Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care. 2005; 28: 1941-1947.
63. Chantelau E. Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy. Ophthalmology. 2002; 109: 2187-2188.
64. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol. 1998; 82: 725-730.
65. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001; 33: 300-306.
66. Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol. 2002; 16: 493-509.
67. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-De-Hoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000; 23: 504-509.
68. Fong DS. Changing times for the management of diabetic retinopathy Surv Ophthalmol. 2002; 47(suppl 2): 238S-245S.
69. Geraldes P, King GL. Activation of rotein Kinase C Isoforms and Its Impact on Diabetic Complications. Circ Res. 2010; 106: 1319-1331.
70. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Visl Sci. 2006; 47: 86-92.
71. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005; 54: 2188-2197.
72. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol. 2007; 125: 318-324.
73. Sampson SR, Cooper DR. Specific protein kinase c isoforms as transducers and modulators of insulin signaling. Mol Genet Metab. 2006; 89: 32-47.
74. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology screening, and novel therapies. Diabetes Care. 2003; 26: 2653-2664.
75. Abu El-Asrar AM, Al-Mezaine HS, Ola MS. Pathophysiology and Management of Diabetic Retinopathy. Expert Rev Ophthalmol. 2009; 4: 627-647.
76. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999; 20: 493-510.
77. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med. 1975; 26: 521-535.
78. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol. 1990; 108: 1234-1244.
79. Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol. 1991; 78: 153-159.
80. Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P. The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications. 1992; 6: 131-137.
81. Van Gerven JM, Boot JP, Lemkes HH, van Best JA. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol. 1994; 87: 355-365.
82. Giugliano D, Ceriello A, Paolisso G Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19: 257-267.
83. Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci. 2007; 48: 3805-3811.
84. Kowluru R Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol. 2001; 38: 179-185.
85. Yam JC, Kwok AK. Update on the treatment of diabetic retinopathy Hong Kong Med J. 2007; 13: 46-60.
86. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döh-men S, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002; 16: 438-440.
87. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005; 54: 1559-1565.
88. Jouseen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy FASEB J. 2004; 18: 1450-1452.
89. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008; 30: 65-84.
90. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Ku-wano M, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 2004; 18: 300-310.
91. Johnson EI, Dunlop ME, Larkins RG Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999; 18: 79-82.
92. Lane LS, Jansen PD, Lahav M, Rudy C. Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmol-ogy. 1982; 89: 763-766.
93. Naveh-Floman N, Moisseiev J. Prostanoids and thromboxane A2 involvement in diabetic retinopathy. Metab Pediatr Syst Ophthalmol. 1982; 6: 321-325.
94. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase- 2 and nitric oxide. Curr Pharm Des. 2004; 10: 3331-3148.
95. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxy-genase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003; 458: 283-289.
96. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döh-men S, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002; 16: 438-440.
97. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001; 50: 1636-1642.
98. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007; 56: 373-379.
99. Powell ED, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet. 1964; 2: 17-18.
100. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens. 2002; 16(suppl 3): 42S-46S.
101. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010; 55: 108-133.
102. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabeticmacular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005; 46: 3845-3849.
103. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121: 57-61.
104. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Am J Ophthalmol. 2002; 109: 920-927.
105. Xiao-lu Y, Kun L, Xun X. Update on treatments of diabetic macular edema, review article. Chin Med J. 2009; 122: 2784-2790.
106. Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes mellitus and related disorders. Clin Exp Hypertens. 1999; 21: 121-136.
107. Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001; 119: 709-717.
108. Ryan EH Jr, Han DP, Ramsay RC, Cantrill HL, Bennett SR, Dev S, et al. Diabetic macular edema associated with glitazone use. Retina. 2006; 26: 562-570.
109. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmpl. 2009; 147: 583-586.
110. Iwafune Y, Yoshimoto H. Clinical use of pentoxifylline in haemor-rhagic disorders of the retina. Pharmatherapeutica. 1980; 2: 429-438.
111. Gardner TW, Eller AW, Friberg TR, D'Antonio JA, Hollis TM. Antihistamines reduce blood-retinal barrier permeability in type I (insulin-dependent) diabetic patients with nonproliferative retinopathy: a pilot study. Retina. 1995; 15: 134-140.